OREANDA-NEWS. GE Healthcare, a leader in technology innovation, today announced it will resell Caradigm's Single Sign-On and Context Management solutions in the United States, Canada, and specific EU countries to provide connectivity between the Omnyx™ digital pathology platforms and designated Anatomic Pathology Laboratory Information Systems (APLIS).

When pathologists diagnose cancers, they evaluate tissue in the context of a patient's history, order more tests on the tissue if necessary, and deliver their findings to an oncologist*. The oncologist then uses the pathologist's report to determine the course of treatment. For pathologists, the combination of Omnyx and APLIS software solutions to view whole slide images and to render patient reports streamlines the completion of these tasks.

The collaboration with Caradigm streamlines the workflow of pathologists by using Caradigm's Single Sign-On and Context Management software from its Identity and Access Management (IAM) suite of products to connect the Omnyx™ platform and the APLIS to give pathologists quicker, more secure access to laboratory applications and patient data.

"Digital pathology will enable pathologists to collaborate with other clinicians and patients. This level of connectivity is essential to derive patient-centered care and efficiency," says Mamar Gelaye, CEO, Omnyx. "Using Caradigm Single Sign-On and Context Management software in conjunction with Omnyx solutions, the pathologist will confidently be able to have the right access to the right application and the right data without interruption to their clinical workflow."

Sandy Murti, Vice President of Partnerships & Alliances for Caradigm, added, "Caradigm's IAM products are designed exclusively to meet the complex needs of healthcare organizations challenged to make the right data available at the right time to the right caregivers. We're excited to work with GE Healthcare and Omnyx to make it easier for pathologists to rapidly and securely access data as they provide care for cancer patients."

*In the US, the OmnyxTM IDP is for in vitro diagnostic use for a specific clinical application, and is intended for research use only on other applications.

OmnyxTM is a trademark of Omnyx, LLC.

Caradigm® is a trademark of Caradigm USA LLC.